Oslo 31 Quotes

Department of Chronic Diseases at the Norwegian Institute of Public Health in Oslo, Norway. Participants in the study included 23,122,522 Nordic country residents ages 12 and older. Researchers observed the highest risk in males between 16 and 24 years of age after receiving the second Moderna mRNA-1273 (Incident Rate Ratio of 13.83 and a 95% CI of 8.08 to 23.68) or Pfizer BNT162b2 (Incident Rate Ratio of 5.31 and a 95% CI of 3.68 to 7.68) mRNA vaccine.

The survival rate for myocarditis is 80% after one year and 50% after five years.20 Figure 10.7 shows results from the paper “SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents,” published in the journal JAMA Cardiology in 2022.21 The lead author, Dr. Oystein Karlstad, is affiliated with the Department of Chronic Diseases at the Norwegian Institute of Public Health in Oslo, Norway. Participants in the study included 23,122,522 Nordic country residents ages 12 and older. Researchers observed the highest risk in males between 16 and 24 years of age after receiving the second Moderna mRNA-1273 (Incident Rate Ratio of 13.83 and a 95% CI of 8.08 to 23.68) or Pfizer BNT162b2 (Incident Rate Ratio of 5.31 and a 95% CI of 3.68 to 7.68) mRNA vaccine.